China's approach to innovative pharmaceutical R&D: A review

The Chemical and Pharmaceutical Industry in China: Opportunities and Threats for Foreign Companies

Volumn , Issue , 2005, Pages 121-132

  Webber, David E ^a  

^a WSMI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 73749088040     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-26561-9_10     Document Type: Chapter

References (4)

1. Sponsorship of this work and of the summary here by the R&D-Based Pharmaceutical Association in China (RDPAC) is gratefully acknowledged.
2. By 2000, the Chinese pharmaceutical industry had become the second largest supplier of bulk pharmaceuticals in the world, with output of 33,000 tons of antibiotics, 29,000 tons of vitamin products and 45,000 tons of sulfanilamides, analgesics and antipyretics (IMS CHINA UPDATE, Issue 75, February 2000).
3. See Webber 2003b for a discussion of R&D models. The state-managed approach also suffers from problems with skills, knowledge & facilities, goal orientation and financing.
4. Contrast with the Singapore Economic Development Board's S$ 1 billion (US$ 550 million) R&D fund set up in June 2000 to attract foreign companies. The Research Incentive Scheme for Companies in Singapore provides up to 50 percent of the total research expenditure of a company over five years.